Clinical & Scientific

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

The firm reports a $195M cash reserve but a wider net loss as it nears crucial data readouts for its novel depression and anxiety drug candidates.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

A new plant-derived drug shows promise in preventing prostate cancer and improving cholesterol, but the company faces significant financial hurdles ahead.

A new drug, JIN-A02, shows early promise in overcoming resistance to common lung cancer therapies, even shrinking hard-to-treat brain metastases.

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

A new collaboration with Datavant will securely connect real-world health data, aiming to speed up research and deliver life-saving therapies faster.

Insight Molecular Diagnostics secures $26M to expand its transplant rejection test to the heart market, backed by a major shareholder amid market dilution concerns.

SOFIE Biosciences' FAPI-PRO trial begins, testing a novel radiotracer that could revolutionize the detection of one of the deadliest forms of cancer.

Health Canada grants conditional approval to BioMarin's VOXZOGO, the first drug in the country to target the genetic cause of achondroplasia.

With a new CEO and stunning clinical data, BOOST Pharma advances a potential game-changer for children with the rare genetic disorder Osteogenesis Imperfecta.

A new pilot program uses AI to find hidden patterns in past cancer trial data, aiming to get the right drugs to the right patients, faster.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

A groundbreaking dual-payload ADC from Kanghong Pharmaceutical has entered clinical trials, a major milestone in oncology accelerated by partner BioDlink.

A new German partnership aims to create variant-ready, room-temperature stable vaccines, moving beyond the limits of first-generation mRNA technology.

Ernexa Therapeutics secures crucial funding for its cancer therapy pipeline, but the dilutive offering sends its stock plunging more than 50%.

Delonix Bioworks' next-gen meningitis B vaccine, DX-104, is cleared for human trials in China and Australia, aiming to challenge the market leaders.